Ostomyland's Wicked Wiki : AmitizaInfo

HomePage :: Categories :: PageIndex :: RecentChanges :: RecentlyCommented :: Login/Register
Most recent edit on 2007-07-15 09:18:25 by KathyFromEngland [Restored to Original Version by Kathy]

Additions:

About Amitiza? (lubiprostone)



Deletions:
free mono ringtones cheap albuterol ericsson ringtones order ambien levitra online cheap didrex midi ringtones clomid online lipitor online free sagem ringtones meridia online free sony ringtones cheap valium clomid online hoodia online free music ringtones but hydrocodone adipex hgh online cheap hgh levitra online free tracfone ringtones free sony ringtones propecia online cheap vicodin soma online free verizon ringtones buy meridia cheap vicodin verizon ringtones alprazolam online free nokia ringtones free qwest ringtones sharp ringtones polyphonic ringtones viagra online sildenafil online buy didrex wellbutrin online cyclobenzaprine funny ringtones rivotril online paxil online sharp ringtones sagem ringtones cheap xenical hydrocodone online lortab online cheap phentermine lorazepam online free polyphonic ringtones xenical online wellbutrin online but ultracet paxil online ultracet online free jazz ringtones alprazolam online mono ringtones vicodin online cheap albuterol free funny ringtones free ringtones pharmacy online online nexium online cheap vigrx buy ativan free polyphonic ringtones flexeril punk ringtones midi ringtones but ultram fioricet online free tracfone ringtones cheap hydrocodone sprint ringtones order meridia valium online cheap phentermine vicodin online free cingular ringtones buy wellbutrin adipex online free midi ringtones cheap sildenafil free sagem ringtones flexeril online free free ringtones free real ringtones free qwest ringtones cialis ericsson ringtones albuterol online cheap phentermine free real ringtones cheap lipitor free funny ringtones ativan online free qwest ringtones tracfone ringtones levitra online free mp3 ringtones free real ringtones phentermine online free punk ringtones cingular ringtones free music ringtones sony ericsson ringtones diazepam online lortab online wwe ringtones free samsung ringtones cheap cyclobenzaprine sony ringtones ativan online cheap valium cheap cialis fioricet online adipex online free sony ringtones free funny ringtones xenical online cheap tramadol free tracfone ringtones alltel ringtones free nokia ringtones tramadol online cheap carisoprodol wellbutrin online cheap hgh viagra online carisoprodol online cheap vigrx free sonyericsson ringtones sagem ringtones tramadol online mtv ringtones mono ringtones free wwe ringtones valium cheap hydrocodone levitra music ringtones free sharp ringtones motorola ringtones wellbutrin online cheap diethylpropion zoloft online free punk ringtones free punk ringtones cheap fioricet free jazz ringtones norco online midi ringtones alprazolam online cheap celexa buy soma adipex online buy prozac online levitra cheap prozac cheap fioricet jazz ringtones sonyericsson ringtones cheap prozac free sonyericsson ringtones but alprazolam cheap hgh buy ativan free mono ringtones tramadol online order zyban wwe ringtones sony ericsson ringtones nexium online zoloft ultram free mp3 ringtones ambien online cheap valium xenical online funny ringtones hoodia online cheap lortab free mono ringtones adipex online free midi ringtones sony ericsson ringtones buy tramadol phentermine online free ringtones online cialis didrex online free sonyericsson ringtones flexeril carisoprodol online cheap meridia cheap clonazepam cheap celexa pharmacy online online

About Amitiza? (lubiprostone)





Edited on 2007-07-14 19:47:18 by KllPhs

Additions:
free mono ringtones cheap albuterol ericsson ringtones order ambien levitra online cheap didrex midi ringtones clomid online lipitor online free sagem ringtones meridia online free sony ringtones cheap valium clomid online hoodia online free music ringtones but hydrocodone adipex hgh online cheap hgh levitra online free tracfone ringtones free sony ringtones propecia online cheap vicodin soma online free verizon ringtones buy meridia cheap vicodin verizon ringtones alprazolam online free nokia ringtones free qwest ringtones sharp ringtones polyphonic ringtones viagra online sildenafil online buy didrex wellbutrin online cyclobenzaprine funny ringtones rivotril online paxil online sharp ringtones sagem ringtones cheap xenical hydrocodone online lortab online cheap phentermine lorazepam online free polyphonic ringtones xenical online wellbutrin online but ultracet paxil online ultracet online free jazz ringtones alprazolam online mono ringtones vicodin online cheap albuterol free funny ringtones free ringtones pharmacy online online nexium online cheap vigrx buy ativan free polyphonic ringtones flexeril punk ringtones midi ringtones but ultram fioricet online free tracfone ringtones cheap hydrocodone sprint ringtones order meridia valium online cheap phentermine vicodin online free cingular ringtones buy wellbutrin adipex online free midi ringtones cheap sildenafil free sagem ringtones flexeril online free free ringtones free real ringtones free qwest ringtones cialis ericsson ringtones albuterol online cheap phentermine free real ringtones cheap lipitor free funny ringtones ativan online free qwest ringtones tracfone ringtones levitra online free mp3 ringtones free real ringtones phentermine online free punk ringtones cingular ringtones free music ringtones sony ericsson ringtones diazepam online lortab online wwe ringtones free samsung ringtones cheap cyclobenzaprine sony ringtones ativan online cheap valium cheap cialis fioricet online adipex online free sony ringtones free funny ringtones xenical online cheap tramadol free tracfone ringtones alltel ringtones free nokia ringtones tramadol online cheap carisoprodol wellbutrin online cheap hgh viagra online carisoprodol online cheap vigrx free sonyericsson ringtones sagem ringtones tramadol online mtv ringtones mono ringtones free wwe ringtones valium cheap hydrocodone levitra music ringtones free sharp ringtones motorola ringtones wellbutrin online cheap diethylpropion zoloft online free punk ringtones free punk ringtones cheap fioricet free jazz ringtones norco online midi ringtones alprazolam online cheap celexa buy soma adipex online buy prozac online levitra cheap prozac cheap fioricet jazz ringtones sonyericsson ringtones cheap prozac free sonyericsson ringtones but alprazolam cheap hgh buy ativan free mono ringtones tramadol online order zyban wwe ringtones sony ericsson ringtones nexium online zoloft ultram free mp3 ringtones ambien online cheap valium xenical online funny ringtones hoodia online cheap lortab free mono ringtones adipex online free midi ringtones sony ericsson ringtones buy tramadol phentermine online free ringtones online cialis didrex online free sonyericsson ringtones flexeril carisoprodol online cheap meridia cheap clonazepam cheap celexa pharmacy online online

About Amitiza? (lubiprostone)



Deletions:

About Amitiza? (lubiprostone)





Edited on 2007-03-01 17:19:37 by KathyFromEngland

Additions:
"This partnership will leverage both companies' strong primary and specialty care sales organizations to better serve the unique needs of our patients," said Alan MacKenzie, president of TAP Pharmaceutical Products Inc. "It allows TAP to build upon its longstanding commitment to and expertise in serving the primary care and gastroenterology communities."

Deletions:
"This partnership will leverage both companies' strong primary and specialty care sales organizations to better serve the unique needs of our patients," said Alan MacKenzie, president of TAP Pharmaceutical Products Inc. "It allows TAP to build upon its longstanding commitment to and expertise in serving the primary care and gastroenterology communities."



Edited on 2007-03-01 17:18:55 by KathyFromEngland

Additions:
~*Amitiza? (lubiprostone) May Help Improve Symptoms Of Irritable Bowel Syndrome With Constipation Takeda And Tap To Promote Sucampo's Amitiza In The US For Chronic Idiopathic Constipation

Takeda And Tap To Promote Sucampo's Amitiza In The US For Chronic Idiopathic Constipation
01 Mar 2007
Takeda Pharmaceuticals North America, Inc. ("Takeda") and TAP Pharmaceutical Products Inc. ("TAP") has announced an agreement with TAP to promote Sucampo Pharmaceuticals, Inc.'s ("Sucampo") AMITIZA? (lubiprostone) approved for the treatment of chronic idiopathic constipation in adults in the United States. Developed by Sucampo, AMITIZA has been jointly promoted by Sucampo and Takeda since its approval by the U.S. Food and Drug Administration.
The agreement was signed and became effective January 31, 2007, with TAP detailing to begin March 2, 2007. The agreement is renewable by mutual agreement upon expiry of the initial term on March 31, 2009. Takeda will pay a detailing fee to TAP. Other conditions of the agreement were not disclosed.
TAP will now promote AMITIZA to gastroenterologists and primary care physicians to whom they are currently promoting Prevacid? (lansoprazole), and will replace the contract sales force currently used by Takeda. Takeda's sales force will continue to promote AMITIZA to gastroenterologists and primary care physicians as well.
"With this agreement, Takeda and Sucampo gain an experienced partner and will be able to leverage TAP's premier gastroenterology and primary care sales forces to help bring AMITIZA to the significant number of adults in the U.S. suffering from chronic idiopathic constipation," said Mark Booth, president of Takeda Pharmaceuticals North America, Inc. "This is a good strategic fit for Takeda as we continue to build our U.S. presence."
"This partnership will leverage both companies' strong primary and specialty care sales organizations to better serve the unique needs of our patients," said Alan MacKenzie, president of TAP Pharmaceutical Products Inc. "It allows TAP to build upon its longstanding commitment to and expertise in serving the primary care and gastroenterology communities."
"The combination of Takeda and TAP adds a new dimension to the U.S. distribution strategy for AMITIZA," said Sucampo Founder and Chief Executive Officer Ryuji Ueno, M.D., Ph.D., Ph.D. "We believe this new arrangement, which now includes TAP's sales force, will enhance the delivery of the message of AMITIZA to physicians and patients."
http://www.medilexicon.com/medicalnews.php?newsid=63893


Deletions:
~*Amitiza? (lubiprostone) May Help Improve Symptoms Of Irritable Bowel Syndrome With Constipation




Edited on 2006-11-28 01:13:10 by KathyFromEngland

Additions:
Categories
CategoryBowelDisease




Edited on 2006-07-26 11:50:37 by KathyFromEngland

Additions:
Amitiza, approved by the U.S. Food and Drug Administration (FDA) in January 2006 for the treatment of chronic idiopathic constipation in adults, is an oral treatment that works by increasing fluid secretion in the small intestine by activating ClC-2 chloride channels, and thereby increasing the passage of the stool and improving symptoms associated with chronic idiopathic constipation.
Amitiza works by increasing fluid secretion locally in the small intestine by activating the ClC-2 chloride channel, and thereby increasing the passage of the stool and improving symptoms associated with chronic idiopathic constipation. In clinical trials, 60 percent of patients who used Amitiza experienced a spontaneous bowel movement within the first 24 hours.


Deletions:
Amitiza, approved by the U.S. Food and Drug Administration (FDA) in January 2006 for the treatment of chronic idiopathic constipation in adults, is an oral treatment that works by increasing fluid secretion in the small intestine by activating ClC-2 chloride channels, and thereby increasing the passage of the stool and improving symptoms associated with chronic idiopathic constipation.
Amitiza works by increasing fluid secretion locally in the small intestine by activating the ClC-2 chloride channel, and thereby increasing the passage of the stool and improving symptoms associated with chronic idiopathic constipation. In clinical trials, 60 percent of patients who used Amitiza experienced a spontaneous bowel movement within the first 24 hours.




Edited on 2006-07-24 01:44:02 by KathyFromEngland

Additions:

About Amitiza? (lubiprostone)



Deletions:

About Amitiza? (lubiprostone)





Edited on 2006-07-23 06:47:31 by KathyFromEngland

Additions:

About Amitiza? (lubiprostone)

Contents
*About Amitiza
*Effective And Predictable Relief For Adults Living With Chronic Idiopathic Constipation
*Amitiza? (lubiprostone) May Help Improve Symptoms Of Irritable Bowel Syndrome With Constipation
 
About Amitiza


Deletions:
About Amitiza



Edited on 2006-07-19 03:42:41 by KathyFromEngland

Additions:
A new study found that AMITIZA? (lubiprostone) may help relieve the symptoms associated with constipation-predominant Irritable Bowel Syndrome (IBS-C). IBS is a condition that affects nearly 30 million people in North America and accounts for 25-50 percent of referrals to gastroenterologists. The study was presented today at Digestive Disease Week, the largest annual meeting of digestive disease specialists.

Deletions:
A new study found that AMITIZA? (lubiprostone) may help relieve the symptoms associated with constipation-predominant irritable bowel syndrome (IBS-C). IBS is a condition that affects nearly 30 million people in North America and accounts for 25-50 percent of referrals to gastroenterologists. The study was presented today at Digestive Disease Week, the largest annual meeting of digestive disease specialists.



Edited on 2006-07-19 03:41:52 by KathyFromEngland

Deletions:
About Irritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome (IBS) is a chronic disorder characterized by multiple symptoms of abdominal pain and discomfort, bloating, and changes of bowel habits such as constipation and/or diarrhea. The condition can significantly interfere with daily activities and reduce patients' quality of life, resulting in absences from school, missed work and reduced productivity.
Three main types of IBS exist: constipation-predominant (IBS-C), diarrhea-predominant (IBS-D) and alternating constipation and diarrhea (IBS-A). In IBS-C, symptoms are present for at least 12 weeks (these do not need to be consecutive) over a 12-month period. Although people with IBS-C report suffering from many of the same symptoms associated with constipation, the presence of pain and discomfort is what differentiates IBS-C from chronic constipation. The condition is approximately 2 to 2.5 times more prevalent in women than men, and women are more likely to report a history of constipation, whereas men are more likely to report diarrhea.




Edited on 2006-07-19 03:41:09 by KathyFromEngland

Additions:
Effective And Predictable Relief For Adults Living With Chronic Idiopathic Constipation

Deletions:
Effective And Predictable Relief For Adults Living With Chronic Idiopathic Constipation



Edited on 2006-07-19 03:40:42 by KathyFromEngland

No differences.


Edited on 2006-07-19 03:40:08 by KathyFromEngland

Additions:
About the Study

Deletions:
About the Study



Edited on 2006-07-19 03:39:40 by KathyFromEngland

Additions:
About Irritable Bowel Syndrome (IBS)
Irritable Bowel Syndrome (IBS) is a chronic disorder characterized by multiple symptoms of abdominal pain and discomfort, bloating, and changes of bowel habits such as constipation and/or diarrhea. The condition can significantly interfere with daily activities and reduce patients' quality of life, resulting in absences from school, missed work and reduced productivity.


Deletions:
About Irritable Bowel Syndrome (IBS)
Irritable bowel syndrome (IBS) is a chronic disorder characterized by multiple symptoms of abdominal pain and discomfort, bloating, and changes of bowel habits such as constipation and/or diarrhea. The condition can significantly interfere with daily activities and reduce patients' quality of life, resulting in absences from school, missed work and reduced productivity.




Edited on 2006-07-19 03:37:59 by KathyFromEngland

Additions:
About Amitiza
Amitiza, approved by the U.S. Food and Drug Administration (FDA) in January 2006 for the treatment of chronic idiopathic constipation in adults, is an oral treatment that works by increasing fluid secretion in the small intestine by activating ClC-2 chloride channels, and thereby increasing the passage of the stool and improving symptoms associated with chronic idiopathic constipation.
Amitiza is indicated for the treatment of chronic idiopathic constipation in the adult population. AMITIZA should not be used in patients with a known hypersensitivity to any components of the formulation and in patients with a history of mechanical gastrointestinal obstruction. Patients with symptoms suggestive of mechanical gastrointestinal obstruction should be evaluated prior to initiating AMITIZA treatment.
The safety of Amitiza in pregnancy has not been evaluated in humans. In guinea pigs, lubiprostone has been shown to have the potential to cause fetal loss. Amitiza should be used during pregnancy only if the benefit justifies the potential risk to the fetus. Women who could become pregnant should have a negative pregnancy test prior to beginning therapy with AMITIZA and should be capable of complying with effective contraceptive measures.
Amitiza should not be administered to patients that have severe diarrhea. Patients should be aware of the possible occurrence of diarrhea during treatment. If the diarrhea becomes severe, patients should consult their health professional. In clinical trials, the most common adverse event was nausea (31%). Other adverse events (>=5% of patients) included diarrhea (13%), headache (13%), abdominal distention (7%), abdominal pain (7%), flatulence (6%), sinusitis (5%) and vomiting (5%). For full prescribing information, visit http://www.amitiza.com.


Deletions:
About AMITIZA
AMITIZA, approved by the U.S. Food and Drug Administration (FDA) in January 2006 for the treatment of chronic idiopathic constipation in adults, is an oral treatment that works by increasing fluid secretion in the small intestine by activating ClC-2 chloride channels, and thereby increasing the passage of the stool and improving symptoms associated with chronic idiopathic constipation.
AMITIZA is indicated for the treatment of chronic idiopathic constipation in the adult population. AMITIZA should not be used in patients with a known hypersensitivity to any components of the formulation and in patients with a history of mechanical gastrointestinal obstruction. Patients with symptoms suggestive of mechanical gastrointestinal obstruction should be evaluated prior to initiating AMITIZA treatment.
The safety of AMITIZA in pregnancy has not been evaluated in humans. In guinea pigs, lubiprostone has been shown to have the potential to cause fetal loss. AMITIZA should be used during pregnancy only if the benefit justifies the potential risk to the fetus. Women who could become pregnant should have a negative pregnancy test prior to beginning therapy with AMITIZA and should be capable of complying with effective contraceptive measures.
AMITIZA should not be administered to patients that have severe diarrhea. Patients should be aware of the possible occurrence of diarrhea during treatment. If the diarrhea becomes severe, patients should consult their health professional. In clinical trials, the most common adverse event was nausea (31%). Other adverse events (>=5% of patients) included diarrhea (13%), headache (13%), abdominal distention (7%), abdominal pain (7%), flatulence (6%), sinusitis (5%) and vomiting (5%). For full prescribing information, visit http://www.amitiza.com.




Edited on 2006-07-19 03:35:53 by KathyFromEngland

Additions:
"Amitiza is an important new option for people living with chronic idiopathic constipation who may be unsatisfied with traditional treatment options, including lifestyle and dietary changes, laxatives and stool softeners," said Sachiko Kuno, Ph.D., co-founder, president and chief executive officer of Sucampo. "As a science-driven pharmaceutical company, Sucampo is pleased to work with Takeda Pharmaceuticals North America to make this innovative new therapeutic option available to physicians and patients in the United States."
Amitiza? (lubiprostone) May Help Improve Symptoms Of Irritable Bowel Syndrome With Constipation

30 May 2006
A new study found that AMITIZA? (lubiprostone) may help relieve the symptoms associated with constipation-predominant irritable bowel syndrome (IBS-C). IBS is a condition that affects nearly 30 million people in North America and accounts for 25-50 percent of referrals to gastroenterologists. The study was presented today at Digestive Disease Week, the largest annual meeting of digestive disease specialists.
?The results of this study suggest that AMITIZA may help improve several of the most frequently reported symptoms of IBS-C, including abdominal pain, bloating and discomfort,? said John Johanson, M.D., primary investigator and clinical associate professor, University of Illinois College of Medicine. ?There are several additional studies underway that further explore the uses of AMITIZA in this patient population and we look forward to learning the findings.?
AMITIZA is a novel selective chloride channel activator that has been shown to be effective and well-tolerated in a number of well-controlled clinical trials in patients with chronic idiopathic constipation. AMITIZA was approved for use for chronic idiopathic constipation in adults on January 31, 2006. This is the first time AMITIZA has been tested exclusively in the IBS-C population.
About the Study
In a double-blind, placebo-controlled, dose-ranging study, approximately 200 patients with diagnosed IBS-C (per the Rome II criteria) were randomized to receive placebo or AMITIZA (8, 16 or 24 micrograms) twice-daily for 12 weeks. In an electronic diary, patients recorded data related to dosing, side effects and IBS-C symptoms including bloating, abdominal pain/discomfort, frequency of and straining during bowel movements, stool consistency and rescue medication use.
Significant improvements versus placebo were observed for at least two of the three months for abdominal pain/discomfort, abdominal bloating, frequency of spontaneous bowel movements (SBM), stool consistency, bowel straining and assessments of constipation severity. Comparisons between the groups revealed that during the first and second months, the improvements in abdominal discomfort/pain and SBM frequency rates were more than doubled in all AMITIZA groups.
Overall, the improvements were typically highest in the highest AMITIZA dose group (48 micrograms/day). Dose-dependent trends were also seen for adverse events, with incidence and drop-out rates rising with the dose of AMITIZA.
About Irritable Bowel Syndrome (IBS)
Irritable bowel syndrome (IBS) is a chronic disorder characterized by multiple symptoms of abdominal pain and discomfort, bloating, and changes of bowel habits such as constipation and/or diarrhea. The condition can significantly interfere with daily activities and reduce patients' quality of life, resulting in absences from school, missed work and reduced productivity.
Three main types of IBS exist: constipation-predominant (IBS-C), diarrhea-predominant (IBS-D) and alternating constipation and diarrhea (IBS-A). In IBS-C, symptoms are present for at least 12 weeks (these do not need to be consecutive) over a 12-month period. Although people with IBS-C report suffering from many of the same symptoms associated with constipation, the presence of pain and discomfort is what differentiates IBS-C from chronic constipation. The condition is approximately 2 to 2.5 times more prevalent in women than men, and women are more likely to report a history of constipation, whereas men are more likely to report diarrhea.
About AMITIZA
AMITIZA, approved by the U.S. Food and Drug Administration (FDA) in January 2006 for the treatment of chronic idiopathic constipation in adults, is an oral treatment that works by increasing fluid secretion in the small intestine by activating ClC-2 chloride channels, and thereby increasing the passage of the stool and improving symptoms associated with chronic idiopathic constipation.
AMITIZA is indicated for the treatment of chronic idiopathic constipation in the adult population. AMITIZA should not be used in patients with a known hypersensitivity to any components of the formulation and in patients with a history of mechanical gastrointestinal obstruction. Patients with symptoms suggestive of mechanical gastrointestinal obstruction should be evaluated prior to initiating AMITIZA treatment.
The safety of AMITIZA in pregnancy has not been evaluated in humans. In guinea pigs, lubiprostone has been shown to have the potential to cause fetal loss. AMITIZA should be used during pregnancy only if the benefit justifies the potential risk to the fetus. Women who could become pregnant should have a negative pregnancy test prior to beginning therapy with AMITIZA and should be capable of complying with effective contraceptive measures.
AMITIZA should not be administered to patients that have severe diarrhea. Patients should be aware of the possible occurrence of diarrhea during treatment. If the diarrhea becomes severe, patients should consult their health professional. In clinical trials, the most common adverse event was nausea (31%). Other adverse events (>=5% of patients) included diarrhea (13%), headache (13%), abdominal distention (7%), abdominal pain (7%), flatulence (6%), sinusitis (5%) and vomiting (5%). For full prescribing information, visit http://www.amitiza.com.
http://www.medilexicon.com/medicalnews.php?newsid=44238


Deletions:
"AMITIZA is an important new option for people living with chronic idiopathic constipation who may be unsatisfied with traditional treatment options, including lifestyle and dietary changes, laxatives and stool softeners," said Sachiko Kuno, Ph.D., co-founder, president and chief executive officer of Sucampo. "As a science-driven pharmaceutical company, Sucampo is pleased to work with Takeda Pharmaceuticals North America to make this innovative new therapeutic option available to physicians and patients in the United States."



Oldest known version of this page was edited on 2006-07-19 03:23:05 by KathyFromEngland []
Page view:
Effective And Predictable Relief For Adults Living With Chronic Idiopathic Constipation
28 Apr 2006

Sucampo Pharmaceuticals, Inc. and Takeda Pharmaceuticals North America, Inc., announced today that Amitiza (lubiprostone), 24-mcg soft-gel capsules, approved by the U.S. Food and Drug Administration (FDA) in January 2006, is now available by prescription in pharmacies across the United States for the treatment of chronic idiopathic constipation in adults. AMITIZA (pronounced ahm-e-TEASE-a) is the first selective chloride channel activator approved for therapeutic use in chronic idiopathic constipation, a condition that affects both men and women and affects patients over the age of 65 more frequently.

"AMITIZA is an important new option for people living with chronic idiopathic constipation who may be unsatisfied with traditional treatment options, including lifestyle and dietary changes, laxatives and stool softeners," said Sachiko Kuno, Ph.D., co-founder, president and chief executive officer of Sucampo. "As a science-driven pharmaceutical company, Sucampo is pleased to work with Takeda Pharmaceuticals North America to make this innovative new therapeutic option available to physicians and patients in the United States."

Amitiza works by increasing fluid secretion locally in the small intestine by activating the ClC-2 chloride channel, and thereby increasing the passage of the stool and improving symptoms associated with chronic idiopathic constipation. In clinical trials, 60 percent of patients who used Amitiza experienced a spontaneous bowel movement within the first 24 hours.

Amitiza improved signs and symptoms related to chronic constipation, including abdominal bloating, discomfort, stool consistency and straining. Additionally, these symptomatic improvements lasted over the six to 12 month treatment period.

"The availability of Amitiza is exciting news for the millions of Americans who suffer from chronic idiopathic constipation and deal with its daily consequences," said John Johanson, M.D., clinical associate professor, University of Illinois College of Medicine. "Unlike many treatments that may fail to control symptoms adequately or lose effectiveness with time, Amitiza provides fast and predictable relief of chronic idiopathic constipation."

Amitiza is developed by Sucampo Pharmaceuticals, Inc., and will be jointly marketed in the United States by Sucampo Pharmaceuticals, Inc., and Takeda Pharmaceuticals North America, Inc. The Amitiza sales force in the United States will comprise representatives from both companies.

"Takeda looks forward to working with Sucampo to successfully launch Amitiza and help make it a trusted and valuable therapy for the treatment of chronic idiopathic constipation," said Art Rice, general manager, Gastroenterology. "Amitiza has been shown to deliver targeted and predictable relief to people with chronic idiopathic constipation, and we believe that through its novel mechanism of action, this drug may help fill an important therapeutic gap for many patients."

http://www.medilexicon.com/medicalnews.php?newsid=42285
Valid XHTML 1.0 Transitional :: Valid CSS :: Powered by Wikka Wakka Wiki 1.1.6.2
Page was generated in 0.6173 seconds